Current and novel therapeutic strategies for optimizing immunotherapy outcomes in advanced non-small cell lung cancer

During the past decade, immunotherapy has dramatically improved the outcomes of patients with non-small cell lung cancer (NSCLC). The development of specific antibodies against the programmed death (PD1) receptor and its ligand PD-L1 (programmed death ligand-1) has demonstrated substantial efficacy...

Descripción completa

Detalles Bibliográficos
Autores principales: Martin, Claudio, Enrico, Diego
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Oncology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9772042/
https://www.ncbi.nlm.nih.gov/pubmed/36568253
http://dx.doi.org/10.3389/fonc.2022.962947

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9772042/
https://www.ncbi.nlm.nih.gov/pubmed/36568253
http://dx.doi.org/10.3389/fonc.2022.962947

Ejemplares similares